Advanced Solid Malignancies Recruiting Phase 3 Trials for Durvalumab (DB11714)

Also known as: Advanced Solid Malignancy

IndicationStatusPhase
DBCOND0034803 (Advanced Solid Malignancies)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03084471An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.Treatment